The bufo experience is 5-MeO-DMT — vaporised from the dried secretions of Incilius alvarius, the Sonoran Desert toad, or from synthetic sources. The active phase lasts 20–45 minutes. Onset takes 15 seconds or less. What follows is not imagery, not narrative, not the geometry you get from psilocybin or ayahuasca. It is ego dissolution — a direct encounter with the structure of experience itself, with the self removed from the centre of it. Some people describe it as the most significant thing that has ever happened to them. Some describe it as the most distressing. The difference is not random.
The bufo experience is inhalation of vaporised 5-MeO-DMT — from Incilius alvarius (the Sonoran Desert toad) or synthetic sources. It produces acute ego dissolution in 20–45 minutes. Onset takes under 15 seconds. The mechanism involves serotonin 1A receptor agonism and sigma-1 receptor activity. The acute experience is non-visual and non-narrative. Recovery and integration require a minimum of 2–3 days.
What Is the Bufo Experience?
The Sonoran Desert toad — Incilius alvarius — produces a venom containing 5-MeO-DMT at approximately 15–25% concentration by weight. Traditionally, the secretions were dried and the residue vaporised. Synthetic 5-MeO-DMT produces an identical molecular compound. The bufo alvarius ceremony uses the toad-derived source. Some providers now use synthetic 5-MeO-DMT, which avoids the conservation concerns associated with milking wild toads.
The administration is inhalation. A single deep breath of the vapour is typically sufficient for a full-strength experience. Effects begin within 15 seconds. The peak state — the period of most intense ego dissolution — arrives within one to two minutes and lasts 10–20 minutes. The total active experience runs 20–45 minutes. Recovery — the period of supervised rest before a person is oriented and physically stable — adds another one to two hours. The 2–3 day integration period begins after that.
The character of the bufo experience is unlike iboga, ayahuasca, or psilocybin. Those medicines tend to produce visual content, personal memory, narrative, or symbolic imagery. The bufo experience tends to produce none of these — or to dissolve them before they can form. What remains is not story. It is a state of awareness without a self at the centre of it, which is difficult to describe and impossible to anticipate accurately from the outside. People consistently report that no prior description of the experience prepared them for it.
Bufo ceremony at Transcend in Vancouver uses 5-MeO-DMT with a trained facilitator present throughout. The 2–3 day recovery period is structured. The experience itself is not the end of the process.
What 5-MeO-DMT Does in the Brain
Psilocybin and LSD act primarily on serotonin 2A receptors. This is why they produce vivid visual content and narrative experiences — the 5-HT2A receptor is involved in visual cortex processing and associative thinking. 5-MeO-DMT acts primarily on serotonin 1A receptors. This is a different receptor with different functions, and it produces a different kind of experience.
Serotonin 1A (5-HT1A) receptors are widely distributed throughout the brain but are concentrated in the raphe nuclei and limbic system — regions involved in emotion regulation, stress response, and the default mode network. When 5-MeO-DMT binds to these receptors with high affinity, the activity of the default mode network — the brain system responsible for self-referential thinking, autobiographical memory, and the sense of being a continuous self through time — collapses. The result is what researchers call oceanic boundlessness: a state of undifferentiated awareness with no persistent self at its centre.
5-MeO-DMT also acts on sigma-1 receptors, which are involved in neuroprotection and cellular stress response. This may contribute to the sense of profound rest and reduced inflammation that some people report in the days following the experience. The sigma-1 mechanism is less studied than the serotonin pathway but is an active area of research.
What 5-MeO-DMT does not do: it does not inhibit MAO. This matters for safety. Ayahuasca contains MAO inhibitors — the harmala alkaloids in Banisteriopsis caapi that allow DMT to survive oral digestion. If you have recently used ayahuasca, the residual MAOI activity in your system amplifies 5-MeO-DMT dramatically and dangerously. A minimum two-week separation between ayahuasca and bufo ceremony is required. Three to four weeks is more prudent.
What the Research Shows
The most cited study on the bufo experience is a 2019 Johns Hopkins survey of 362 people who had used 5-MeO-DMT in a naturalistic setting. Among those who reported a prior diagnosis of depression — 41% of respondents — 80% reported improvement following their experience. Among those with anxiety — 48% of respondents — 79% reported improvement. These numbers come from a survey, not a controlled trial. They describe self-reported retrospective outcomes, not clinical measurements. The direction of the findings is consistent with what practitioners observe. The methodology is not strong enough to constitute proof.
A 2023 case study published in Frontiers in Psychiatry followed a single patient with treatment-resistant PTSD who received a bufo alvarius ceremony containing approximately 10–15 mg of 5-MeO-DMT. The improvements in PTSD symptoms were clinically significant immediately after and held at one, three, six, and twelve months of follow-up. A single case is not a clinical trial. It is notable precisely because PTSD symptoms in this population do not typically remit spontaneously.
Controlled clinical evidence is developing. A 2023 trial by Reckweg et al. examined synthetic 5-MeO-DMT in treatment-resistant depression — 16 patients, with significant reductions in symptoms at 24 hours and approximately half of patients in remission after one week. These are small numbers at early stages of study design. The Johns Hopkins data and the Frontiers PTSD case are the most accessible starting points for anyone researching this area.
The evidence base for 5-MeO-DMT is smaller and younger than the evidence base for ibogaine or psilocybin. The direction is consistent — improvement in depression, anxiety, and trauma measures — and the absence of definitive trials reflects the constraints of research on Schedule I and analogous compounds, not a verdict on clinical potential.
What Ego Dissolution Actually Feels Like
This is the section that is hardest to write accurately and most commonly written badly. Here is what the clinical literature and practitioner observation actually support:
The onset is fast and does not build gradually. Within seconds of inhalation, the ordinary structures of perception — self, time, location, continuity — begin to dissolve. For some people this is experienced as expansion: a merging with everything, a profound sense of unity and the absence of suffering. For others it is experienced as annihilation: the loss of the self before any comfort or context can establish itself.
The experience tends to be non-visual. There is no dream logic, no symbolic content, no personal memory playing out. What remains — when ordinary perception is stripped away — is not nothing. It is a quality of awareness that most people do not have a vocabulary for before the experience and struggle to describe accurately after it.
Physical responses during the experience vary: some people cry without knowing why, some laugh, some shake or move involuntarily. Some are silent and completely still. These are normal responses to the medicine's effects on the limbic and motor systems. They do not require intervention from the facilitator unless someone is at risk of physical harm.
5-MeO-DMT is not a lighter version of ibogaine. It is shorter, not easier. The intensity of ego dissolution in 20–45 minutes produces its own demands, and the absence of narrative content makes integration harder, not simpler. There is no story to unpack. There is only the experience itself — which has to be metabolised differently.
People who come expecting a pleasant or expansive altered state are consistently surprised by how direct the experience is. The medicine does not accommodate avoidance.
For more on how bufo compares to iboga over a 12–24 hour ceremony, the 5-MeO-DMT vs ibogaine comparison covers the differences in mechanism, duration, and clinical application.
The Integration Period
The acute bufo experience ends within an hour. What it produces does not.
The 2–3 days after the ceremony are a period of physical rest and initial stabilisation. Sleep patterns are often disrupted. Emotional processing continues, sometimes intensely. This period requires a supported environment — not immediate return to ordinary responsibilities or demanding social contexts.
Beyond the first few days, the integration period extends for weeks. This is where the work of making meaning from the experience happens. Without it, the experience fades into an unusually vivid memory — one that the person cannot quite explain and cannot quite place within the rest of their life. The ceremony opens something. What is done with that depends entirely on the weeks that follow.
Integration after 5-MeO-DMT is harder than integration after narrative psychedelics for a specific reason: there is no content to work with directly. Psilocybin therapy typically produces memories, symbols, and scenes that can be reflected on, discussed, and worked through systematically. The bufo experience does not provide these handles. The integration is more somatic, more experiential, and requires a different approach — one that focuses on embodying the state rather than interpreting its content.
This is why integration support is not optional. The people who have clear lasting change from bufo ceremony are typically those who had deliberate support in place — structured check-ins, a practice, and someone to work with who understands what this experience produces. The people who did not have this in place often find themselves back where they started within six weeks, holding an experience they cannot integrate and a contrast between what was possible and what they returned to.
Transcend offers integration coaching specifically designed for the bufo experience and the distinct challenges of working without narrative content. The integration guide covers what this process involves in practice.
Who This Is Not For
5-MeO-DMT has a specific set of contraindications. Some are absolute. Some require preparation before ceremony becomes possible.
- Recent use of MAOIs or ayahuasca. Harmala alkaloids in ayahuasca inhibit MAO — the enzyme that breaks down 5-MeO-DMT. If MAOI activity is present, a standard 5-MeO-DMT dose can produce an experience of many times the intended intensity. This has caused deaths. A minimum two to three week separation is required; four weeks is safer. Antidepressants that function as MAO inhibitors (phenelzine, tranylcypromine) are absolute contraindications.
- SSRIs and SNRIs. 5-MeO-DMT acts on the serotonin system. Combining it with SSRIs or SNRIs carries real risk of serotonin syndrome — excess serotonin receptor stimulation that in severe cases is fatal. A supervised taper under physician oversight is required before bufo ceremony. This is not optional and cannot be self-managed.
- Cardiac conditions. 5-MeO-DMT is not associated with the same degree of QT prolongation as ibogaine, but cardiovascular conditions still require assessment. An EKG is required before ceremony. Significant arrhythmia is a contraindication.
- Active psychosis or schizophrenia spectrum disorder. 5-MeO-DMT can destabilise psychotic conditions. Active psychosis is an absolute contraindication. A history of a psychotic episode requires careful psychiatric evaluation — not an automatic exclusion, but a thorough assessment.
- Pregnancy. Absolute contraindication. No exceptions.
- Lithium. Combining 5-MeO-DMT with lithium has been associated with serious adverse effects. An absolute contraindication.
- Someone in acute psychiatric crisis. The experience amplifies what is present. Entering it in a destabilised state does not produce stability.
- Someone seeking an experience. People who come primarily for the phenomenon — the "most intense experience of my life" — rather than for a specific therapeutic purpose leave disappointed, or leave with something they are not equipped to process. The medicine is not a novelty. Treating it as one is not an appropriate intention for ceremony.
We tell people they are not an appropriate candidate directly, without softening it. The screening process exists to identify these situations before ceremony — not during it. For full contraindications across both ibogaine and 5-MeO-DMT, the FAQ covers these in detail.
Is This Right for You?
The bufo experience is appropriate for people who are treatment-resistant in the conventional sense: depression, anxiety, trauma, or PTSD that has not resolved through standard approaches, and who have done the assessment work to confirm they are not contraindicated. It is not appropriate as a first step, as a curiosity, or for people in acute destabilisation.
If you are considering bufo ceremony in Vancouver, the FAQ covers who this is and is not for, what the screening process involves, and what to expect from the preparation and integration periods. The ceremony page describes what the process looks like at Transcend specifically.
5-MeO-DMT ceremony at Transcend costs $600–$1,500 CAD. Medical screening — including EKG and blood panel — is required before any decision about ceremony. The application begins that process. We respond personally within 2–3 business days.
The bufo experience is shorter than iboga. It is not lighter. Understanding that distinction before you decide is the point of this page.
Sources: Johns Hopkins 5-MeO-DMT survey / Psychopharmacology (2019) · 5-MeO-DMT for PTSD / Frontiers in Psychiatry (2023) · Satisfaction with life and psychopathology after 5-MeO-DMT / PMC (2019)